Isatuximab

ATC L01FC02 · 9 markets · 22 records

Isatuximab 9 markets · 22 records Forms

US 3 records · 3 strengths

500 mg/25 mLinjectionSarclisa also in GB
100 mg/5 mLinjectionSarclisa also in GB
140 mginjectionSarclisa Escena

GB 3 records · 3 strengths

500 mg/25 mLinjectionSarclisa 100mg/5ml concentrate for solution for infusion vials also in US
100 mg/5 mLinjectionSarclisa 100mg/5ml concentrate for solution for infusion vials also in US
1,400 mg/10 mLinjectionSarclisa 1400mg/10ml solution for injection vials

CA 3 records · 2 strengths

140 mg/1 mLliquidSARCLISA SC
20 mg/1 mLliquidSarclisa

AU 3 records · 3 strengths

500 mginjectionSARCLISA isatuximab 500 mg/25 mL concentrated injection vial unknown
100 mginjectionSARCLISA isatuximab 500 mg/25 mL concentrated injection vial unknown

Records without a stated strength · 1 Sarclisa

ES 2 records · 2 strengths

1,400 mginjectionSarclisa
20 mg/1 mLinjectionSarclisa

HK 2 records · 1 strengths

Records without a stated strength · 1 SARCLISA CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/5ML

SG 1 records · 1 strengths

20 mg/mLinjectionSARCLISA concentrate for solution for infusion 20 mg/mL

TW 1 records · 1 strengths

20 mginjectionSARCLISA concentrate for solution for infusion 20 mg/mL+1多髓易濃縮輸注液20毫克/毫升

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Sarclisa

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.